Cargando…

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and (18)F-FMISO PET

Tumoral hypoxia correlates with worse outcomes in glioblastoma (GBM). While bevacizumab is routinely used to treat recurrent GBM, it may exacerbate hypoxia. Evofosfamide is a hypoxia-targeting prodrug being tested for recurrent GBM. To characterize resistance to bevacizumab and identify those with r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Shiliang, Michalek, Joel E., Reardon, David A., Wen, Patrick Y., Floyd, John R., Fox, Peter T., Clarke, Geoffrey D., Jerabek, Paul A., Schmainda, Kathleen M., Muzi, Mark, Hyun, Hyewon, Lee, Eudocia Quant, Brenner, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027395/ https://www.ncbi.nlm.nih.gov/pubmed/33828310 http://dx.doi.org/10.1038/s41598-021-84331-5

Ejemplares similares

Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma
por: Brenner, Andrew J., et al.
Publicado: (2021)

ANGI-1 ASSESSING THE THERAPEUTIC EFFECT OF BEVACIZUMAB USING FMISO-PET IN GBM THERAPY
por: Suzuki, Tomoya, et al.
Publicado: (2022)

A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using (18)F-FMISO-PET
por: Rockne, Russell C., et al.
Publicado: (2015)

Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide
por: Lodi, Alessia, et al.
Publicado: (2022)

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer
por: Yoon, Jeesun, et al.
Publicado: (2021)

Usefulness of FMISO—PET for Glioma Analysis
por: Kobayashi, Hiroyuki, et al.
Publicado: (2013)

Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
por: Wiedenmann, Nicole, et al.
Publicado: (2018)

FMISO-PET-derived brain oxygen tension maps: application to glioblastoma and less aggressive gliomas
por: Chakhoyan, Ararat, et al.
Publicado: (2017)

Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
por: Wiedenmann, Nicole, et al.
Publicado: (2018)

Monitoring Tumor Hypoxia Using (18)F-FMISO PET and Pharmacokinetics Modeling after Photodynamic Therapy
por: Tong, Xiao, et al.
Publicado: (2016)

The role of necrosis, acute hypoxia and chronic hypoxia in (18)F-FMISO PET image contrast: a computational modelling study
por: Warren, Daniel R, et al.
Publicado: (2016)

Elimination of tumor hypoxia by eribulin demonstrated by (18)F-FMISO hypoxia imaging in human tumor xenograft models
por: Zhao, Songji, et al.
Publicado: (2019)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
por: Lee, Eudocia Q., et al.
Publicado: (2019)

Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients
por: Bandurska-Luque, Anna, et al.
Publicado: (2019)

Biodistribution and radiation dosimetry of the novel hypoxia PET probe [(18)F]DiFA and comparison with [(18)F]FMISO
por: Watanabe, Shiro, et al.
Publicado: (2019)

First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer
por: Thureau, Sébastien, et al.
Publicado: (2021)

Synthesis of [(18)F]FMISO, a hypoxia-specific imaging probe for PET, an overview from a radiochemist’s perspective
por: Kniess, Torsten, et al.
Publicado: (2023)

Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, (18)F-FMISO PET, and (18)F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
por: Collet, Solène, et al.
Publicado: (2021)

Increased [(18)F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors
por: Shimizu, Yoichi, et al.
Publicado: (2021)

(18)F-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-Radiotherapy
por: Carles, Montserrat, et al.
Publicado: (2021)

Assessment of the Prognostic Value of Radiomic Features in (18)F-FMISO PET Imaging of Hypoxia in Postsurgery Brain Cancer Patients: Secondary Analysis of Imaging Data from a Single-Center Study and the Multicenter ACRIN 6684 Trial
por: Muzi, Mark, et al.
Publicado: (2020)

The accumulation mechanism of the hypoxia imaging probe “FMISO” by imaging mass spectrometry: possible involvement of low-molecular metabolites
por: Masaki, Yukiko, et al.
Publicado: (2015)

Kinetic Evaluation of the Hypoxia Radiotracers [(18)F]FMISO and [(18)F]FAZA in Dogs with Spontaneous Tumors Using Dynamic PET/CT Imaging
por: Choen, Sangkyung, et al.
Publicado: (2022)

FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer
por: Dolezel, Martin, et al.
Publicado: (2022)

Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma
por: Mao, Xing-gang, et al.
Publicado: (2016)

FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer
por: Thureau, Sébastien, et al.
Publicado: (2018)

Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence
por: Christ, Sebastian M., et al.
Publicado: (2023)

Hypoxia Imaging Using PET and SPECT: The Effects of Anesthetic and Carrier Gas on [(64)Cu]-ATSM, [(99m)Tc]-HL91 and [(18)F]-FMISO Tumor Hypoxia Accumulation
por: Kersemans, Veerle, et al.
Publicado: (2011)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

[(18)F]FMISO PET/CT as a preoperative prognostic factor in patients with pancreatic cancer
por: Yamane, Tomohiko, et al.
Publicado: (2019)

Quantitative MRI to Characterize Hypoxic Tumors in Comparison to FMISO PET/CT for Radiotherapy in Oropharynx Cancers
por: Gouel, Pierrick, et al.
Publicado: (2023)

Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625
por: Boxerman, Jerrold L., et al.
Publicado: (2023)

(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
por: Reeves, Kirsten M., et al.
Publicado: (2022)

Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas
por: Suzuki, Kenta, et al.
Publicado: (2021)

Comparison of DCE‐MRI kinetic parameters and FMISO‐PET uptake parameters in head and neck cancer patients
por: Simoncic, Urban, et al.
Publicado: (2017)

Local relapse of nasopharyngeal cancer and Voxel-based analysis of FMISO uptake using PET with semiconductor detectors
por: Nishikawa, Yukiko, et al.
Publicado: (2017)

Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine
por: Barajas, Ramon F., et al.
Publicado: (2016)

Parametric Response Maps of Perfusion MRI May Identify Recurrent Glioblastomas Responsive to Bevacizumab and Irinotecan
por: Aquino, Domenico, et al.
Publicado: (2014)

Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients
por: Gerstner, Elizabeth R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1hqotm7qrp05qujv7dl89trnnf